John McAdam is the Chairman of ConvaTec Group plc. John is also Chairman of United Utilities Group plc since 2008. He is also Senior Independent Director of Cobham plc, a position he has held since August 2017. John has previously been a Non-Executive Director of Wilmcote Holdings plc and of a number of FTSE 100 and US companies, including Rolls-Royce Group plc, J Sainsbury plc and The Sara Lee Corporation. He spent more than two decades at Unilever before joining ICI, where he became Chief Executive in 2003 until its takeover by Akzo Nobel in 2008. Previously, John was Chairman of Rentokil Initial plc from 2008; he stepped down from this role earlier in 2019. With 20 years' service as a board director, including as Chairman and Chief Executive Officer in companies undertaking transformation, John has a wealth of experience on which to draw in his role as Chairman and leader of the Board. John has a BSc (Hons) Chemical Physics, a Diploma in Advanced Studies in Science and a PhD.
Karim Bitar is Chief Executive Officer of ConvaTec Group plc. Previously, Karim was Chief Executive Officer of Genus plc, a leading global agricultural biotechnology company. During his eight-year tenure, he helped transform Genus into a technology pioneer with leading global franchises in dairy, beef and pork genetics. Prior to this, Karim worked for over 15 years with Eli Lilly & Company and was President of Lilly Europe, Canada and Australia before joining Genus. An ex- McKinsey & Company consultant, he worked across Asia and Europe, and also held management roles at Johnson & Johnson and the Dow Chemical Company. Karim is a Non-Executive Director of Spectris Plc, a leading global analytical instrumentation company, and a member of the University of Michigan Ross School of Business Advisory Board. Karim has a Masters (Hons) in Business Administration, University of Michigan, Ross School of Business and a Bachelor of Science in Biochemistry, University of Wisconsin.
Frank was previously CFO of Wittur Group, a privately-held industrial company based in Germany, prior to which he spent 27 years with GE in a variety of increasingly senior financial leadership roles. In 2007 he was appointed Executive Vice President and CFO of GE Healthcare, a position he held until mid-2015 when he left to join Wittur. GE Healthcare is a Global medical technology, life sciences and services company with $18b in revenues. Frank graduated with an Economics degree and a Master’s in Business Economics from the University of Tilburg in the Netherlands.
Mrs Ewing joined the Board in August 2017. She is currently a Non-Executive Director and Chair of the Audit and Risk Committee of ITV plc and a Non-Executive Director and Chair of the Audit and Compliance Committee of International Consolidated Airlines Group, S.A. Mrs Ewing has held Non-Executive Director roles with Standard Chartered plc, Whitbread plc and the Confederation of British Industry and was also the Independent External member of the Audit Committee of the John Lewis Partnership. From 1987-1999, she was a corporate finance partner of Deloitte LLP and returned to the firm in 2007 as a Vice Chairman and latterly as Managing Partner, before retiring in 2012. Mrs Ewing was Group Chief Financial Officer of Trinity Mirror plc from 2000 – 2002 and Chief Financial Officer of BAA PLC from 2002 – 2006.
Mr Anderson has 25 years of senior executive leadership experience in the medical device industry. He is the Chairman and Managing Director of Revival Healthcare Capital, prior to which he served as a Managing Director at PTV Healthcare Capital. He was previously a Group Chairman of Johnson & Johnson and Worldwide Franchise Chairman of Cordis Corporation. Mr. Anderson also served as President of Cordis Corporation and was previously Worldwide Franchise Vice President of Centocor, Inc., which merged with Johnson & Johnson in 1999. Before joining Johnson & Johnson, Mr. Anderson was Vice President of Global Marketing of Racal HealthCare, Inc. and, prior to that, he was spent 10 years with Boehringer Mannheim Pharmaceuticals and Allergan Pharmaceuticals in various US and global sales, sales management, and marketing management roles. Mr. Anderson currently sits on the board of PTV portfolio company Apollo Endosurgery and is the Chairman of the Board for Cardiva Medical. He holds a B.B.A. in Marketing from Mississippi State University.
Dr Benjamin joined the Board in August 2017 as a Non-Executive Director. From 2009 – 2013, she was the United States Surgeon General and is currently a Non-Executive Director of Diplomat Pharmacy, Inc, Kaiser Foundation Hospitals and Health Plan, and Ascension Hospital System. From 1992 – 2004 she served on the board of the Medical Association of Alabama and in 1995 became the first Young Physician to be elected to the American Medical Association Board of Trustees. Dr Benjamin is CEO and a practising physician at the Bayou La Batre Rural Health Clinic in Alabama which she founded in 1990 and holds an endowed chair in Public Health Sciences at Xavier University of Louisiana. In November 2017, she was appointed as a Director of Computer Programs and Systems, Inc.
Mr Scheibye joined the Board in July 2018 as a Non-Executive Director. From 2013 he was Chairman of Novo Holdings A/S and of the Novo Nordisk Foundation, a charitable foundation focused on contributing significantly to research and development that improves the health and welfare of people; he has recently retired from both these positions but currently holds the position of Senior Advisor to Novo Holdings. Mr Scheibye was appointed Chairman of Healthcare Denmark in 2015; prior to that he was a member of the Danish Corporate Governance Committee from 2003 – 2011, serving the last two years as Chairman. From 1995 – 2008 he was the President and CEO of Coloplast A/S.
Constantin joined the Board as a Non-Executive Director in September 2020 and is an internationally recognised key opinion leader in the fields of biomedical engineering, image-guided therapy and drug delivery. Constantin holds a BA, MEng, MA and PhD degrees in Engineering from University of Cambridge and was appointed to the first Statutory Chair in Biomedical Engineering at the University of Oxford in 2011. He is currently the Director of the Institute of Biomedical Engineering at the University of Oxford, which is focused on the disciplines of non-invasive therapies, drug delivery, regenerative medicine, medical imaging, AI in healthcare, neurotechnology and biomaterials. Constantin is also Professor Fellow of Magadalen College and a Trustee of the Oxford Transplant Foundation. Beyond his roles in academia, Constantin also has a proven track record of translating research into technology through entrepreneurship, recognised by the 2017 Silver Medal of the Royal Academy of Engineering. He is the founder and has been CTO/CSO of three successful spin-outs, OrganOx Limited, OxSonics Limited, and OrthoSon Limited, and now serves on each of their boards as a Non-Executive Director. Between 2014 and 2020, he direct and led the Oxford Centre for Drug Delivery Devices, a cross-disciplinary centre working across pharmaceutical and medical device companies and the NHS. In 2019, he was elected a Fellow of the Royal Academy of Engineering.
Brian joined the Board as a Non-Executive Director in March 2020. He is also a Non-Executive Director of United Utilities Group PLC having been appointed in September 2012. Brian was formerly Chief Financial Officer of Bunzl plc from 2006 to 2019 and, prior to that, he held a number of senior management finance roles with Bunzl, including divisional Finance Director, Group Treasurer and Head of Internal Audit. He qualified as a Chartered Accountant with KPMG in 1988.
Heather joined the Board as a Non-Executive Director in July 2020. She is currently a Non-Executive Director and member of the Audit Committee and Compliance Committee of Assertio Therapeutics, Inc., the Nasdaq listed specialty pharmaceutical company. She is Co-Chair of the University of Michigan's College of Engineering Innovation Committee and a member of its Leadership Advisory Board. Heather spent 27 years with Abbott Laboratories where she held a number of global senior operational and strategic leadership roles, including Senior Vice President of Abbott Diabetes Care and most recently, Executive Vice President of Abbot Nutrition. Prior to joining Abbott, Heather worked for Quaker Oats, FMC Corporation, and Commonwealth Edison. Heather holds a B.S.E. in Industrial Engineering from the University of Michigan and an M.B.A. from the University of Chicago.